– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU – – Over $300 million of cash and investments on December 31, 2025, providing runway into Q4 2027 – WATERTOWN, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2025, and highlighted recent corporate developments.